Pfizer stock targets growth beyond patent losses at Jefferies
Published on 11/17/2026 at 14:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPfizer's pipeline strategy takes center stage
- CEO Albert Bourla said recently launched products are growing strongly as Pfizer prepares for patent losses through 2028.
- The company has delivered 7.2 billion US dollars in net savings and announced another 1.5 billion US dollars in reductions.
- Pfizer plans further clinical development in obesity, oncology and immunology while targeting high single-digit growth from 2028 to 2033.
At the Jefferies Global Healthcare Conference on Tuesday, November 17, Pfizer CEO Albert Bourla outlined how the drugmaker plans to navigate its loss-of-exclusivity period and return to growth beyond 2028, according to a Reuters report published by Investing.com.
Pfizer stock traded at 26.13 euros on Lang & Schwarz at 14:16 CET on Tuesday, November 17, 0.80 percent below the Xetra close of Monday, November 16.
Launch products support the transition
Bourla said recently launched products are growing 32 percent year over year and have reached an annualized revenue run rate of 15 billion to 16 billion US dollars. He presented the growth as an early sign that investments made after the Covid-19 pandemic are helping Pfizer build new revenue streams as older medicines approach patent expiry.
The chief executive said Pfizer has invested 80 billion US dollars in acquisitions since the pandemic. The purchases were intended to add platforms, products and development programs rather than relying on individual assets. Bourla said the loss-of-exclusivity period is expected to continue through 2028, with Pfizer targeting high single-digit growth between 2028 and 2033.
Cost actions and pipeline expansion
Pfizer has achieved 7.2 billion US dollars in net savings, which Bourla expects to realize fully by year-end. The company has also announced a further 1.5 billion US dollars in reductions. Management described artificial intelligence as a potential productivity lever across support functions, sales and marketing, with the objective of increasing output while lowering the cost base.
The development pipeline is another part of the strategy. Pfizer said it started 20 Phase III studies in 2026, nearly twice as many as in the previous year. Bourla pointed to oncology programs in breast, prostate, lung cancer and multiple myeloma, as well as a trispecific antibody program in atopic dermatitis. A head-to-head study against Dupixent is intended to test the latter program's potential in a competitive market.
Obesity program remains a key bet
Pfizer is positioning its investigational obesity treatment around monthly dosing. Bourla said consumer research shows a strong preference for monthly rather than weekly treatment, while clinical studies still need to confirm comparable efficacy and tolerability. The company is also studying whether patients who have reached a weight-loss plateau on weekly treatments can maintain their weight after switching to a monthly product.
The discussion gives investors several milestones to monitor: further clinical readouts, progress in the oncology pipeline and the delivery of the announced cost savings. Pfizer's ability to convert those programs into commercial growth will be important as established franchises such as Ibrance and Xtandi face patent pressure.
Pfizer stock facts
- Company: Pfizer Inc.
- ISIN: US7170811035
- Home exchange: New York Stock Exchange
- Lang & Schwarz quote: 26.13 euros on Tuesday, November 17, 2026, at 14:16 CET
- Xetra close: 26.34 euros on Monday, November 16, 2026
- Daily difference: 0.80 percent below the Xetra close
The broader U.S. market is represented by the S&P 500.
